End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
160.8 MXN | -.--% | -.--% | -.--% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 22.15M 373M | Sales 2025 * | 343M 31.73M 534M | Capitalization | 2.37B 219M 3.69B |
---|---|---|---|---|---|
Net income 2024 * | -735M -68.07M -1.15B | Net income 2025 * | -712M -65.94M -1.11B | EV / Sales 2024 * | 11.9 x |
Net Debt 2024 * | 474M 43.9M 739M | Net Debt 2025 * | 733M 67.92M 1.14B | EV / Sales 2025 * | 9.05 x |
P/E ratio 2024 * |
-3.25
x | P/E ratio 2025 * |
-3.86
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- HNSA Stock
- HNSA N Stock